David R. Gandara, MD | Authors

Articles

Comparing Alectinib Versus Crizotinib in ALK+ NSCLC

November 13, 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+ non–small cell lung cancer (NSCLC).

Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung Cancer

August 18, 2017

David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses the combination of CTLA-4 agents with PD-1 and PD-L1 agents for the treatment of lung cancer.